Daniel Blair, PhD

Read how St. Jude is reaching out to youth for HIV education and prevention, including a clinical trial for an HIV prevention and treatment drug.

A new model explains key factors in chronic pain development, and future pain research designed to answer overlooked questions

Newly approved Vitrakvi (larotrectinib) scored high patient response rates by inhibiting a rare chromosomal abnormality that drives tumor growth.

Will a new genome sequencing data mining technique reveal the mother lode of secrets for treating cancer and other catastrophic diseases?

Learn how St. Jude and World Health Organization are taking on the six most common childhood cancers to improve global survival rates.

A recently discovered mutation that occurs when the flu virus is exposed Xofluza could also cause drug resistance.

Suicidal thoughts or actions are not the end – don’t believe these myths associated with suicide.

For 12 years, science didn’t know how certain immune responses were activated. They do now, and it may lead to new cancer treatments.

New findings from St. Jude study Genomes 4 Kids suggest many actionable mutations are missed without a three-platform genomic sequencing approach that includes WGS.

Is precision medicine the next frontier of discovery for cancer cures? This scientist says, for some patients, it may be.